GSK Investigational Site

Marousi 15125

1 studies enrolling now · 6 studies all time

What they study most

BRCA1 Gene Mutation, BRCA2 Gene Mutation, Carcinoma of Breast, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Lung Cancer, Non-Small Cell, Neoplasms, Neoplasms, Breast, Neoplasms, Head and Neck, Ovarian Neoplasms, Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma, Pulmonary Disease, Chronic Obstructive

Studies at this site

• Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2) — Recruiting now
• A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202 — Running, not enrolling
• A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer — Running, not enrolling
• A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer — Running, not enrolling
• A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients — Stopped early
• GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer — Stopped early